A single “MoCRA compliance” slide hides the only distinction that matters: already law versus still being written. FDA’s 2026 Voices post is a status board, not a new obligation.
Members Timeline tracker
US
MoCRA 2026 status board: live duties vs leftover rules
Owner takeaway
Column A (do now): facility listing, product listing, AE process, US contact.
Column B (watch): GMP rule, fragrance-allergen rule, asbestos method (withdrawn Nov 2025).
Column C (state): PFAS and chemical lists — FDA’s PFAS report is not a shield.
If a vendor cannot say which column they are selling, do not buy the project.
Why this now
FDA Voices (May 2026) plus a year of slipped rulemakings.
Who is affected
US and foreign brands selling in the United States.
What to do
Monitor
FDA MoCRA page + Federal Register for the leftover trio.
Prepare
Keep talc and PFAS files current even without a final method/ban.
Act
Fix listing drift this quarter. Do not rebuild the factory on a proposed GMP.
Analysis
Unlock full analysis
Owner takeaway stays free. Choose a plan on the membership page to read the full decision memo comfortably — paid plans also include Workbench and Verify credits.
Sources & related
Linked news
Regulation hubs
Track updates in Workbench, or upgrade for full Regulatory Details and follow-up tools.